See more : Oscotec Inc. (039200.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of Silence Therapeutics plc (SLN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Silence Therapeutics plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- South Atlantic Bancshares, Inc. (SABK) Income Statement Analysis – Financial Results
- Santam Ltd (SNT.JO) Income Statement Analysis – Financial Results
- Kalo Gold Corp. (KLGDF) Income Statement Analysis – Financial Results
- Advanced Share Registry Limited (ASW.AX) Income Statement Analysis – Financial Results
- WSFX Global Pay Limited (WSFX.BO) Income Statement Analysis – Financial Results
Silence Therapeutics plc (SLN)
About Silence Therapeutics plc
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.38M | 17.50M | 12.42M | 5.48M | 244.00K | 0.00 | 16.00K | 770.00K | 0.00 | 15.00K | 117.00K | 163.00K | 694.00K | 2.37M | 1.72M | 2.21M | 4.05M | 1.95M | 509.00K | 159.00K | 1.34M | 1.15M | 138.00K | 959.00K | 1.37M | 210.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 10.32M | 10.88M | 7.46M | 3.76M | 0.00 | 9.74M | 7.94M | 8.71M | 7.11M | 8.88M | 5.65M | 3.38M | 3.36M | 5.82M | 5.07M | 6.71M | 4.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 15.06M | 6.62M | 4.96M | 1.72M | 244.00K | -9.74M | -7.93M | -7.94M | -7.11M | -8.87M | -5.53M | -3.22M | -2.67M | -3.46M | -3.35M | -4.50M | -796.00K | 1.95M | 509.00K | 159.00K | 1.34M | 1.15M | 138.00K | 959.00K | 1.37M | 210.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 59.34% | 37.83% | 39.94% | 31.34% | 100.00% | 0.00% | -49,543.75% | -1,031.30% | 0.00% | -59,126.67% | -4,727.35% | -1,972.39% | -384.29% | -146.03% | -194.43% | -203.85% | -19.67% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 44.03M | 35.61M | 30.77M | 20.21M | 13.34M | 9.74M | 7.94M | 8.71M | 7.11M | 8.88M | 5.65M | 3.38M | 3.36M | 5.82M | 5.07M | 6.71M | 4.84M | 3.19M | 1.66M | 1.70M | 3.01M | 2.46M | 2.49M | 3.00M | 3.05M | 1.68M | 1.83M | 986.00K | 790.00K |
| General & Administrative | 20.64M | 19.61M | 20.01M | 13.98M | 9.64M | 10.83M | 6.46M | 3.97M | 2.66M | 3.26M | 3.54M | 2.61M | 2.65M | 5.13M | 3.19M | 3.29M | 4.99M | 3.03M | 2.75M | 1.83M | 1.01M | 700.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.64M | 19.61M | 20.01M | 13.98M | 9.64M | 10.83M | 6.46M | 3.97M | 2.66M | 3.26M | 3.54M | 2.61M | 2.65M | 5.13M | 3.19M | 3.29M | 4.99M | 3.03M | 2.75M | 1.83M | 1.01M | 700.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 3.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -269.00K | 7.00K | -112.00K | -20.00K | 72.00K | -154.00K | -21.00K | 56.00K | -1.00K | -216.00K | -287.00K | 673.00K | 693.00K | 503.00K | 429.00K | 329.00K | 258.00K | 143.00K |
| Operating Expenses | 64.66M | 55.21M | 50.77M | 37.56M | 22.98M | 20.57M | 14.41M | 12.68M | 9.77M | 12.14M | 9.19M | 5.99M | 2.65M | 5.13M | 4.18M | 3.29M | 4.84M | 6.21M | 4.40M | 3.53M | 4.02M | 3.16M | 3.17M | 3.69M | 3.55M | 2.11M | 2.16M | 1.24M | 933.00K |
| Cost & Expenses | 74.98M | 66.09M | 58.23M | 41.33M | 22.98M | 20.57M | 14.41M | 12.68M | 9.77M | 12.14M | 9.19M | 5.99M | 6.01M | 10.95M | 9.26M | 10.00M | 9.68M | 6.21M | 4.40M | 3.53M | 4.02M | 3.16M | 3.17M | 3.69M | 3.55M | 2.11M | 2.16M | 1.24M | 933.00K |
| Interest Income | 1.45M | 226.00K | 10.00K | 129.00K | 27.00K | 39.00K | 206.00K | 1.54M | 175.00K | 147.00K | 70.00K | 18.00K | 56.00K | 95.00K | 46.00K | 357.00K | 544.00K | 348.00K | 264.00K | 133.00K | 216.00K | 317.00K | 522.00K | 505.00K | 163.00K | 324.00K | 398.00K | 279.00K | 59.00K |
| Interest Expense | 34.00K | 47.00K | 8.00K | 323.00K | 163.00K | 0.00 | 15.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.00K | 63.00K | 0.00 | -31.00K | 0.00 | 20.00K | 1.00K | 71.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -398.00K | -279.00K | -59.00K |
| Depreciation & Amortization | 498.00K | 482.00K | 427.00K | 496.00K | 482.00K | 399.00K | 433.00K | 310.00K | 182.00K | 332.00K | 297.00K | 252.00K | 305.00K | 323.00K | 371.00K | 423.00K | 318.00K | 353.00K | 216.00K | 38.00K | 44.00K | 56.00K | 42.00K | 29.00K | 6.00K | 36.00K | 34.00K | 34.00K | 1.00K |
| EBITDA | -49.78M | -47.89M | -45.42M | -35.53M | -22.36M | -20.17M | -3.33M | -11.60M | -9.59M | -11.80M | -8.78M | -5.31M | -5.42M | -8.17M | -7.12M | -7.44M | -5.32M | -3.59M | -3.42M | -3.20M | -2.63M | -1.95M | -2.99M | -2.71M | -2.17M | -1.87M | -2.13M | -1.21M | -932.00K |
| EBITDA Ratio | -196.17% | -273.61% | -365.50% | -642.85% | -9,108.61% | 0.00% | -208,962.50% | -1,505.97% | 0.00% | -78,633.33% | -7,500.00% | -3,409.82% | -713.69% | -345.31% | -413.06% | -317.43% | -117.91% | -183.10% | -669.94% | -2,010.06% | -179.54% | -143.09% | -2,163.04% | -282.17% | -158.61% | -889.05% | 0.00% | 0.00% | 0.00% |
| Operating Income | -49.60M | -48.59M | -45.81M | -35.85M | -22.73M | -20.57M | -14.39M | -11.91M | -9.77M | -12.13M | -9.07M | -26.31M | -5.79M | -8.66M | -7.55M | -7.79M | -5.79M | -4.27M | -3.90M | -3.37M | -2.67M | -2.01M | -3.03M | -2.74M | -2.18M | -1.90M | -2.16M | -1.24M | -933.00K |
| Operating Income Ratio | -195.48% | -277.66% | -369.02% | -654.26% | -9,317.21% | 0.00% | -89,943.75% | -1,546.23% | 0.00% | -80,846.67% | -7,753.85% | -16,143.56% | -833.72% | -365.93% | -438.42% | -352.74% | -143.02% | -219.21% | -765.82% | -2,118.24% | -198.88% | -174.20% | -2,193.48% | -285.19% | -159.05% | -906.19% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -706.00K | 1.23M | -42.00K | -194.00K | -136.00K | 45.00K | 10.62M | 1.54M | 340.00K | 147.00K | 70.00K | -20.46M | 49.00K | -137.00K | 46.00K | 357.00K | 544.00K | 328.00K | 263.00K | 62.00K | 216.00K | 302.00K | 479.00K | 505.00K | 163.00K | 324.00K | 398.00K | 279.00K | 59.00K |
| Income Before Tax | -50.31M | -47.37M | -45.86M | -36.04M | -22.87M | -20.53M | -3.78M | -10.36M | -9.43M | -11.98M | -9.00M | -26.28M | -5.74M | -8.80M | -7.51M | -7.44M | -5.24M | -3.94M | -3.64M | -3.31M | -2.46M | -1.70M | -2.55M | -2.23M | -2.02M | -1.58M | -1.76M | -965.00K | -874.00K |
| Income Before Tax Ratio | -198.27% | -270.66% | -369.36% | -657.80% | -9,372.95% | 0.00% | -23,593.75% | -1,345.71% | 0.00% | -79,866.67% | -7,694.02% | -16,125.15% | -826.66% | -371.72% | -435.75% | -336.58% | -129.58% | -202.36% | -714.15% | -2,079.25% | -182.81% | -147.96% | -1,846.38% | -232.53% | -147.15% | -751.90% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -7.04M | -6.88M | -6.45M | -3.49M | -3.29M | -2.12M | -2.16M | -1.92M | -2.78M | -892.00K | -70.00K | -30.00K | -49.00K | 137.00K | -37.00K | -357.00K | -136.00K | -114.00K | -50.00K | -350.00K | -177.00K | -220.00K | -354.00K | -286.00K | 124.00K | -324.00K | -398.00K | -279.00K | -59.00K |
| Net Income | -43.27M | -40.49M | -39.41M | -32.55M | -19.58M | -18.41M | -1.62M | -8.44M | -6.65M | -11.09M | -9.00M | -26.28M | -5.74M | -8.80M | -7.47M | -7.44M | -5.11M | -3.83M | -3.59M | -2.96M | -2.28M | -1.48M | -2.19M | -1.94M | -2.14M | -1.58M | -1.76M | -965.00K | -874.00K |
| Net Income Ratio | -170.51% | -231.35% | -317.44% | -594.03% | -8,025.41% | 0.00% | -10,112.50% | -1,096.10% | 0.00% | -73,920.00% | -7,694.02% | -16,125.15% | -826.66% | -371.72% | -433.60% | -336.58% | -126.22% | -196.51% | -704.32% | -1,859.12% | -169.64% | -128.84% | -1,589.86% | -202.71% | -156.20% | -751.90% | 0.00% | 0.00% | 0.00% |
| EPS | -1.17 | -1.26 | -1.33 | -1.19 | -0.78 | -0.79 | -0.07 | -0.36 | -0.31 | -0.66 | -0.61 | -4.11 | -1.84 | -4.74 | -8.32 | -9.30 | -6.59 | -6.03 | -8.83 | -18.57 | -14.33 | -9.32 | -13.79 | -12.77 | -15.59 | -12.00 | -13.68 | -7.59 | -7.95 |
| EPS Diluted | -1.17 | -1.26 | -1.33 | -1.19 | -0.78 | -0.79 | -0.07 | -0.36 | -0.31 | -0.66 | -0.61 | -4.11 | -1.84 | -4.74 | -8.32 | -9.30 | -6.59 | -6.03 | -8.83 | -18.57 | -14.33 | -9.32 | -13.79 | -12.77 | -15.59 | -12.00 | -13.68 | -7.59 | -7.95 |
| Weighted Avg Shares Out | 37.09M | 32.19M | 29.65M | 27.26M | 25.04M | 23.44M | 23.31M | 23.27M | 21.34M | 16.81M | 14.64M | 6.39M | 3.11M | 1.86M | 897.60K | 799.24K | 775.31K | 634.26K | 405.84K | 159.15K | 159.07K | 159.07K | 159.07K | 152.23K | 137.25K | 131.57K | 128.69K | 127.20K | 109.93K |
| Weighted Avg Shares Out (Dil) | 37.09M | 32.19M | 29.65M | 27.26M | 25.04M | 23.44M | 23.31M | 23.27M | 21.34M | 16.81M | 14.64M | 6.39M | 3.11M | 1.86M | 897.60K | 799.24K | 775.31K | 634.26K | 405.84K | 159.15K | 159.07K | 159.07K | 159.07K | 152.23K | 137.25K | 131.57K | 128.69K | 127.20K | 109.93K |
Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that it has completed enrollment in the ALPACAR-360...
Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that it has completed enrollment in the ALPACAR-360 phase 2...
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference
LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Company management will participate in a fireside chat at...
Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera
LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced publication of human genomic and in vivo preclinical data linking...
Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced publication of human genomic and in vivo preclinical...
Silence Therapeutics to Present at Guggenheim’s Genomic Medicines and Rare Disease Days
LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Company management will participate in a virtual fireside chat...
Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development
LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the appointment of Steven Romano, MD, as incoming Chief Medical...
Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced the appointment of Steven Romano, MD, as incoming...
Silence Therapeutics to Buyback siRNA Complement Assets
LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced it will be acquiring back exclusive worldwide rights to two...
Silence Therapeutics to Buyback siRNA Complement Assets
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced it will be acquiring back exclusive worldwide rights...
Source: https://incomestatements.info
Category: Stock Reports